Gliosarcoma with features of chondroblastic osteosarcoma

Hayashi, Kazuhiko; Ohara, Nobuya; Jeon, Ho Jong; Akagi, Seiko; Takahashi, Kiyoshi; Akagi, Tadaatsu; Namba, Sayaka

doi:10.1002/1097-0142(19930801)72:3<850::aid-cncr2820720334>3.0.co;2-4

Cited by 39 publications

(19 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 In our study, all cases of osteosarcomas were positive for GFAP. The strongest expression was documented in tumors with chondroblastic differentiation.…”

Section: Discussionsupporting

confidence: 53%

“…[2][3][4][5][6] GFAP is the most specific marker for cells of astrocytic origin under normal and pathological conditions. By immunohistochemistry, however, GFAP has been shown to be expressed in mesenchymal tumors, such as soft tissue myoepitheliomas, peripheral nerve sheath tumors, and chordomas, 3,[7][8][9][10][11][12] and also in mixed tumors, such as salivary gland pleomorphic adenomas. 13,14 These findings can create problems for the diagnosis of tumors that have similar morphologies and are positive for GFAP, such as myoepithelioma and chondroblastic osteosarcoma of the head and neck.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Glial fibrillary acidic protein in tumor types with cartilaginous differentiation

et al. 2009

View full text Add to dashboard Cite

Glial fibrillary acidic protein (GFAP) is a member of the intermediary filament protein family. It is an important component of astrocytes and a known diagnostic marker of glial differentiation. GFAP is expressed in other neural tumors and pleomorphic adenoma and, less frequently, in cartilage tumors, chordomas, and soft tissue myoepitheliomas. The aim of this study was to evaluate the role of GFAP and its reliability in nonglial tumors as an immunohistochemical marker. We evaluated GFAP gene and protein expression using Q-PCR and immunohistochemistry, respectively, in 81 and 387 cases of soft tissue, bone tumors, and salivary pleomorphic adenomas. Immunohistochemistry staining for GFAP was observed in all osteosarcomas (8 cases), all pleomorphic adenomas (7 cases), in 5 of 6 soft tissue myoepitheliomas, and in 21 of 76 chondrosarcomas. By Q-PCR, GFAP was highly expressed in pleomorphic adenomas and, to a lesser extent, chondrosarcomas, soft tissue myoepitheliomas, and chondroblastic osteosarcomas. The results that we obtained by immunohistochemistry and Q-PCR were well correlated. GFAP is a potential marker for tumors with cartilaginous differentiation, supported by evidence that GFAP is expressed in certain cases of myoepithelial tumors by immunohistochemistry, including soft tissue myoepitheliomas, which are related to cartilaginous differentiation. These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors.

show abstract

“…9 In our study, all cases of osteosarcomas were positive for GFAP. The strongest expression was documented in tumors with chondroblastic differentiation.…”

Section: Discussionsupporting

confidence: 53%

mentioning

confidence: 99%

Glial fibrillary acidic protein in tumor types with cartilaginous differentiation

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Epithelial differentiation with carcinomatous features can also occur in glial portions [115]. The sarcomatous component of this tumour shows atypical, aggressive features and can differentiate along multiple distinct lineages, such as fibroblastic, osteogenic, chondrogenic, adipogenic, and myogenic types, especially upon exposure to radiation treatment [2,7,8,10,52,89,139]. A similar potential variant termed gliofibroma has also been described consisting of biphasic glial and non-sarcomatous fibroblastic components commonly found in paediatric patients [89].…”

Section: Gliosarcomamentioning

confidence: 99%

Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features

Karsy¹,

Gelbman²,

Shah³

et al. 2012

View full text Add to dashboard Cite

A b s t r a c t Since the recent publication of the World Health Organization brain tumour classification guidelines in 2007, a significant expansion in the molecular understanding of glioblastoma multiforme (GBM) and its pathological as well as genomic variants has been evident. The purpose of this review article is to evaluate the histopathological, molecular and clinical features surrounding emerging and currently established GBM variants. The tumours discussed include classic glioblastoma multiforme and its four genomic variants, proneural, neural, mesenchymal, classical, as well as gliosarcoma (GS), and giant cell GBM (gcGBM). Furthermore, the emerging variants include fibrillary/epithelial GBM, small cell astrocytoma (SCA), GBM with oligodendroglial component (GBMO), GBM with primitive neuroectodermal features (GBM-PNET), gemistocytic astrocytoma (GA), granular cell astrocytoma (GCA), and paediatric high-grade glioma (HGG) as well as diffuse intrinsic pontine glioma (DIPG

show abstract

“…Some studies indicate that osteosarcoma cells also arise from progenitor stem cells, although the particular stem cell has not been identified but it is thought to be an osteoprogenitor cell capable of differentiating into phenotypes seen in cartilage and bone [9,17,19,20,55]. We suggest the stem cells giving rise to the cancer may be more primitive than an immediate progenitor cell, ie, a multipotent stem cell.…”

Section: Introductionmentioning

confidence: 85%

“…Ewing's sarcoma contains cells with mesenchymal, epithelial, and neural features [9,10,46]. Sarcoma cells promote neuronal and glial differentiation [19,21,22], which means that the cells with these markers in Ewing's sarcoma could have arisen from nonsarcoma cells. However, none of these studies showed that osteosarcoma cells could differentiate to phenotypes other than cartilage or bone.…”

Section: Introductionmentioning

confidence: 99%